NDA 020629 · Mylan
Denavir
Penciclovir · Topical · Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor
NovelLast checked: Nov 20, 2026Latest source record: Nov 21, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Sep 24, 1996
Approved uses
2
Original approval plus efficacy supplements
Registered trials
4
1 Phase 3, 0 recruiting
FAERS reports
362
217 serious, 24 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 4, 2019.
Penciclovir cream is a deoxynucleoside analog HSV DNA polymerase inhibitor indicated for the treatment of recurrent herpes labialis (cold sores) in adults and children 12 years of age or older. Penciclovir cream is a deoxynucleoside analog HSV DNA polymerase inhibitor indicated for the treatment of recurrent herpes labialis (cold sores) in adults and pediatric patients 12 years of age and older. ( 1 )
Mechanism: Penciclovir is an antiviral agent active against alpha herpes viruses [see Microbiology (12.4) ]. Mechanism of Action Penciclovir has inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2). In cells infected with HSV-1 or HSV-2, the viral thymidine kinase phosphorylates penciclovir to a monophosphate form that, in turn, is converted by cellular kinases to the active form penciclovir triphosphate. Biochemical studies demonstrate that penciclovir triphosphate inhibits HSV DNA polymerase competitively with deoxyguanosine triphosphate. Consequently, α-herpes viral DNA...
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 10, 2003 Supplement 8 · Efficacy LabelLetter
- Sep 24, 1996 Original approval · Type 1 - New Molecular Entity Review
1 products under this application
- DENAVIR · PENCICLOVIR 1% · CREAM, TOPICAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Penciclovir" as an intervention, any sponsor and status, largest first.
- A Comparative Study of the Efficacy of Penciclovir 10mg/g (1%) Cream in Preventing the Appearance of Classical Lesion in Recurrent Cold Sore SufferersPivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00820534 · 126 participants · Start Dec 2008 · Primary completion Nov 2009
Drug: Penciclovir; Placebo · For: Cold Sore
Sites: Belfast, United Kingdom
- Non-inferiority Comparison of Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes LabialisPivotal-lookingCompleted
EMSIndustry
NCT01257074 · 76 participants · Start Feb 2012 · Primary completion Mar 2012
Drug: Acyclovir 50mg/g; Penciclovir 10mg/g · For: Herpes Labialis
Sites: São Paulo, Brazil
University of UtahAcademic, hospital or other
NCT06558838 · 58 participants · Start Aug 19, 2024 · Primary completion Nov 30, 2025
Drug: acyclovir-penciclovir cream; Abreva · For: Herpes Simplex Oral
Sites: Murray, Utah
Second Affiliated Hospital of Xi'an Jiaotong UniversityAcademic, hospital or other
NCT06985589 · 32 participants · Start Jan 1, 2024 · Primary completion Aug 31, 2024
Drug: Cortex Phellodendri compound fluid wet compress; basic treatment · For: Acute Herpes Zoster
Sites: Xi'an, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective46
- headache31
- fatigue28
- pain26
- diarrhoea25
- hypertension22
- chronic kidney disease20
- cough20
- vomiting20
- anaemia18
- condition aggravated18
- nausea18
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 8 |
| 2005 | 6 |
| 2006 | 11 |
| 2007 | 10 |
| 2008 | 6 |
| 2009 | 9 |
| 2010 | 10 |
| 2011 | 14 |
| 2012 | 10 |
| 2013 | 13 |
| 2014 | 8 |
| 2015 | 27 |
| 2016 | 49 |
| 2017 | 28 |
| 2018 | 31 |
| 2019 | 32 |
| 2020 | 20 |
| 2021 | 16 |
| 2022 | 18 |
| 2023 | 9 |
| 2024 | 8 |
| 2025 | 8 |
| 2026 | 11 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Denavir (Penciclovir)
2024 spending
$466K
Beneficiaries
257
518 claims
Per beneficiary
$1,812
$155.22 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $6,527,909 |
| 2021 | $5,566,596 |
| 2022 | $4,882,912 |
| 2023 | $889,206 |
| 2024 | $465,663 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Herpes labialis.
Worrall G · BMJ Clin Evid 2006 · Systematic Review
- A new topical treatment protocol for oral hairy leukoplakia.
Moura MD, Haddad JP, Senna MI, et al. · Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010 · Comparative Study, Randomized Controlled Trial
- Comparison of photobiomodulation therapy with conventional treatment in patients with herpes labialis: a systematic review and meta-analysis of randomized controlled trials.
Yang Q, Farooq W, Haroon M, et al. · Lasers Med Sci 2025 · Systematic Review, Meta-Analysis
- Evaluation of orally administered famciclovir in cats experimentally infected with feline herpesvirus type-1.
Thomasy SM, Lim CC, Reilly CM, et al. · Am J Vet Res 2011 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients.
Peñuelas I, Mazzolini G, Boán JF, et al. · Gastroenterology 2005 · Clinical Trial, Clinical Trial, Phase I
- Pharmacokinetics and safety of penciclovir following oral administration of famciclovir to cats.
Thomasy SM, Maggs DJ, Moulin NK, et al. · Am J Vet Res 2007 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Mylan
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.